Immunicum's dendritic cell therapy flunks co-primary endpoint in 'positive' PhII

Immunicum’s immune priming dendritic cell injection has missed the mark on a Phase II exploratory trial in metastatic kidney cancer, but that’s not stopping the company from casting the results in a positive light and pushing the program into late-stage studies.